Overview
- Editors:
-
-
Michael F. Ochs
-
Sydney Kimmel Comprehensive, Cancer Center, John Hopkins University, Baltimore, USA
-
John T. Casagrande
-
USC / Norris Comprehensive Cancer Ctr., Los Angeles, USA
-
Ramana V. Davuluri
-
Wistar Institute, Philadelphia, USA
Access this book
Other ways to access
Table of contents (20 chapters)
-
Front Matter
Pages i-xviii
-
Concepts, Issues, and Approaches
-
-
- Michael F. Ochs, John T. Casagrande, Ramana V. Davuluri
Pages 3-15
-
- Joyce C. Niland, Layla Rouse
Pages 17-37
-
- Waqas Amin, Hyunseok Peter Kang, Michael J. Becich
Pages 39-71
-
- Tahsin Kurc, Ashish Sharma, Scott Oster, Tony Pan, Shannon Hastings, Stephen Langella et al.
Pages 73-90
-
- Frank J. Manion, William Weems, James McNamee
Pages 91-115
-
-
-
- Vincent J. Carey, Victoria Stodden
Pages 149-175
-
-
Tools and Applications
-
Front Matter
Pages 202-202
-
-
-
- Richard Evans, Mark DeTomaso, Reed Comire, Vaibhav Bora, Jeet Poonater, Aarti Vaishnav et al.
Pages 227-239
-
- Matt Stine, Vicki Beal, Nilesh Dosooye, Yingliang Du, Rama Gundapaneni, Andrew Pappas et al.
Pages 241-251
-
- Juli Klemm, Anand Basu, Ian Fore, Aris Floratos, George Komatsoulis
Pages 253-266
-
- Eleanor Howe, Kristina Holton, Sarita Nair, Daniel Schlauch, Raktim Sinha, John Quackenbush
Pages 267-277
-
- Stephen Langella, Shannon Hastings, Scott Oster, Philip Payne, Frank Siebenlist
Pages 279-290
-
- Roger D. Peng, Duncan Temple Lang
Pages 291-300
About this book
view, showing that multiple molecular pathways must be affected for cancer to develop, but with different specific proteins in each pathway mutated or differentially expressed in a given tumor (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008). Different studies demonstrated that while widespread mutations exist in cancer, not all mutations drive cancer development (Lin et al. 2007). This suggests a need to target only a deleterious subset of aberrant proteins, since any tre- ment must aim to improve health to justify its potential side effects. Treatment for cancer must become highly individualized, focusing on the specific aberrant driver proteins in an individual. This drives a need for informatics in cancer far beyond the need in other diseases. For instance, routine treatment with statins has become widespread for minimizing heart disease, with most patients responding to standard doses (Wilt et al. 2004). In contrast, standard treatment for cancer must become tailored to the molecular phenotype of an individual tumor, with each patient receiving a different combination of therapeutics aimed at the specific aberrant proteins driving the cancer. Tracking the aberrations that drive cancers, identifying biomarkers unique to each individual for molecular-level di- nosis and treatment response, monitoring adverse events and complex dosing schedules, and providing annotated molecular data for ongoing research to improve treatments comprise a major biomedical informatics need.
Editors and Affiliations
-
Sydney Kimmel Comprehensive, Cancer Center, John Hopkins University, Baltimore, USA
Michael F. Ochs
-
USC / Norris Comprehensive Cancer Ctr., Los Angeles, USA
John T. Casagrande
-
Wistar Institute, Philadelphia, USA
Ramana V. Davuluri
